跳到正文
BioPharma Dive· Jacob Bell·· 7 天前精选AI 评分71

Argenx 以 5.5 亿美元首付收购大环肽平台公司 Unnatural Products

Argenx to buy peptide platform in potentially billion-dollar deal

AI 导读

Argenx 于 11 月 9 日宣布收购大环肽(macrocyclic peptides)公司 Unnatural Products,首付现金 5.5 亿美元,若达成特定里程碑还可再支付至多 5.95 亿美元。

推荐理由

交易给出5.5亿美元首付与最高5.95亿美元里程碑,可看出机器学习辅助肽类设计在免疫疾病中的商业化位置。

正文 · 原文

An article from site logo

Dive Brief

For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.

Published Nov. 9, 2026

Jacob Bell's headshot

A drop of liquid is held via a pipette above a row of vials.

Argenx agreed to acquire Unnatural Products, a maker of "macrocyclic peptides," on Nov. 9, 2026. deliormanli via Getty Images

Dive Brief:

  • Argenx, a Netherlands-based biotechnology company focused on antibody drugs, on Monday said it has agreed to acquire a protein specialist in a potentially billion-dollar-plus deal.
  • Unnatural Products has a platform that pairs machine learning, screening and other techniques to engineer “macrocyclic peptides.” These peptides are larger and more complex than typical small molecules, which allows them to more effectively bind to tricky proteins and address some challenging diseases. Yet, they’re still tiny enough that they can be swallowed. Argenx plans to use the platform to develop oral, durable medicines for serious immune-mediated diseases.
  • The acquisition carries a $550 million upfront cash payment. Unnatural Products could receive up to $595 million more if specific milestones are hit. The companies expect their deal to close before the end of the year.

Dive Insight:

Unnatural Products claims macrocyclic peptides hold the potential to unlock targets once thought to be “undruggable.” That premise, along with the California company’s technology platform, proved enticing to both venture capitalists and big-name pharmaceutical firms like Merck & Co. and Novartis.

Argenx was drawn in as well, having already taken a minority stake in Unnatural Products before pursuing a full buyout. In a statement, Argenx CEO Karen Massey said these macrocyclic peptide capabilities are “highly complementary” to her own company’s antibody engineering.

“After working together for more than two years, we also know there is a strong fit in how we work: science first, entrepreneurial and focused on patients,” Massey added. “We want to preserve what has made [Unnatural Products] successful while bringing the strengths of both teams together.”

The Food and Drug Administration has already approved at least a handful of macrocyclic peptide therapies. In 2020, for example, Rhythm Pharmaceuticals’ Imcivree was cleared as a treatment for certain genetic forms of obesity. The following year, Aurinia Pharmaceuticals’ Lupkynis became the first-ever oral medicine for adults with active lupus nephritis.

In 2023, the FDA greenlit a UCB medicine called Zilbrysq for “generalized myasthenia gravis,” a rare autoimmune condition that’s become somewhat of a battleground for several developers. Argenx’s own flagship product, Vyvgart, targets this disease and brought in $4.5 billion in net product sales from January through the end of September.

Thomas Smith, a Leerink Partners analyst who covers Argenx, wrote in a note to clients that the new acquisition “represents potential for longer-term strategic value.” He explained there’s a desire — both in big pharma and in the broader immunology and inflammation research space — to make oral, long-acting therapeutics that are able to be more effective and convenient than conventional biologics.

The Unnatural Products deal, which comes on the heels of Argenx’s potentially $2.2 billion purchase of Forte Biosciences, also “signals further focus on pipeline growth and diversification,” Smith wrote.

Shares of Argenx were up nearly 3% by late Monday morning, to hover around $953 apiece.

来源:BioPharma Dive · biopharmadive.com